脑卒中后性治疗:来自加拿大阿尔伯塔省的一项回顾性队列研究
Lalith Satkunam1,2, Sean P Dukelow3, Jaime C Yu1,2
1Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
概括
这项研究发现,加拿大中风后性 (PSS) 治疗通常涉及口服巴克洛芬,尽管证据有限,但可能过度使用. 焦点肉毒素注射可能被不足使用,这表明需要将PSS护理与改善患者结果的指导方针相协调.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脑卒中后性 (PSS) 显著影响患者的康复和生活质量.
- 了解目前的PSS治疗模式对于优化临床实践和患者护理至关重要.
研究的目的:
- 分析PSS治疗在加拿大阿尔伯塔省的实际使用情况.
- 为了确定PSS的治疗启动,时间和处方者类型的模式.
主要方法:
- 使用2012-2019年的人口级行政数据进行的回顾性队列研究.
- 确定开始PSS治疗的成年人 (诊所访问,肉毒素或特定药物).
- 测量了治疗使用,开始时间和医生的专业;应用了描述性统计数据.
主要成果:
- 口服巴克洛芬是最常见的PSS初始治疗 (60.9%),主要由初级保健医生开处方.
- 焦点肉毒素注射 (23.3%) 主要是由物理医生开的.
- 在中风后的311-348天内开始治疗,这表明可能会有延迟.
结论:
- 有证据表明PSS管理存在差距,包括可能过度使用口服巴克洛芬和不足使用焦点肉毒素.
- 目前的PSS治疗模式可能与基于证据的指导方针不一致.
- 需要进一步的策略来改善PSS护理并提高患者的治疗结果.
更多相关视频
07:35Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System
Published on: December 29, 2023
1.1K
05:28Author Spotlight: Enhancing Upper Limb Rehabilitation in Stroke Patients Through Advanced Robotic and Neuromodulation Technologies
Published on: October 11, 2024
497
相关概念视频
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
